U.S. FDA approves Biogen Alzheimer's drug

U.S. regulators on Monday approved Biogen Inc's (BIIB.O) aducanumab as the first treatment to address an underlying cause of Alzheimer's disease despite controversy over mixed clinical trial results for the drug.